In this study, we investigated the mechanisms of acquired resistance to osimertinib and the alterations in mutant allele frequency and TMB during subsequent afatinib treatment by CAPP-Seq in NSCLC patients with EGFR T790M mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.